Instituto Universitário Egas Moniz (IUEM), Campus Universitário - Quinta da Granja, 2829-511, Monte de Caparica, Portugal.
PharmSci Lab/ Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Campus Universitário - Quinta da Granja, 2829-511, Monte de Caparica, Portugal.
Sci Rep. 2024 Jul 7;14(1):15631. doi: 10.1038/s41598-024-66380-8.
The use of lactose and cow milk protein (CMP) as potential allergens in pharmaceuticals and their ability to cause allergic reactions remains a significant concern in medicine. Lactose, a common pharmaceutical excipient due to its inert, inexpensive, and stable properties, is found in many prescription-only and over-the-counter medications. However, despite their widespread use, individuals with lactose intolerance (LI) or cow milk protein allergy (CMPA) may experience adverse reactions to these excipients. This study investigated the prevalence of lactose and other dairy-derived ingredients in pharmaceuticals marketed in Portugal. Using the Summary of Product Characteristics (SmPC) from the INFOMED database, various medications, including analgesics, antipyretics, non-steroidal anti-inflammatory drugs (NSAIDs), and antiasthmatics, were analyzed. Results showed a high prevalence of dairy-derived excipients, particularly in antiasthmatic drugs (62.6%) and NSAIDs (39%). Although CMP are not explicitly mentioned in SmPCs, the presence of lactose as an ingredient poses a risk of cross-contamination. The findings emphasize the need for healthcare professionals to be aware of potential allergens in medications and the importance of developing lactose-free alternatives to ensure the safety of patients with LI and CMPA. Further research is required to assess the safety and implications of lactose in medicines for these populations.
乳糖和牛奶蛋白(CMP)作为药物中的潜在过敏原的使用及其引起过敏反应的能力仍然是医学领域的一个重大关注点。乳糖是一种常见的药物赋形剂,因其惰性、廉价和稳定的特性而被广泛应用于许多处方药和非处方药中。然而,尽管它们被广泛使用,乳糖不耐受(LI)或牛奶蛋白过敏(CMPA)的个体可能会对这些赋形剂产生不良反应。本研究调查了在葡萄牙市场销售的药物中乳糖和其他乳制品成分的流行情况。本研究使用 INFOMED 数据库中的产品特性摘要(SmPC),分析了各种药物,包括镇痛药、解热药、非甾体抗炎药(NSAIDs)和哮喘药。结果显示,乳制品赋形剂的存在率很高,特别是在哮喘药(62.6%)和 NSAIDs(39%)中。尽管 SmPC 中并未明确提及 CMP,但乳糖作为一种成分的存在存在交叉污染的风险。这些发现强调了医疗保健专业人员需要意识到药物中的潜在过敏原,以及开发无乳糖替代品以确保 LI 和 CMPA 患者安全的重要性。需要进一步研究来评估乳糖在这些人群中药物的安全性和影响。